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Summary
Background A substantial impediment to progress in trials of new therapies in neuromuscular disorders is the absence 
of responsive outcome measures that correlate with patient functional deﬁ cits and are sensitive to early disease 
processes. Irrespective of the primary molecular defect, neuromuscular disorder pathological processes include 
disturbance of intramuscular water distribution followed by intramuscular fat accumulation, both quantiﬁ able by MRI. 
In pathologically distinct neuromuscular disorders, we aimed to determine the comparative responsiveness of MRI 
outcome measures over 1 year, the validity of MRI outcome measures by cross-sectional correlation against functionally 
relevant clinical measures, and the sensitivity of speciﬁ c MRI indices to early muscle water changes before intramuscular 
fat accumulation beyond the healthy control range.
Methods We did a prospective observational cohort study of patients with either Charcot-Marie-Tooth disease 1A or 
inclusion body myositis who were attending the inherited neuropathy or muscle clinics at the Medical Research 
Council (MRC) Centre for Neuromuscular Diseases, National Hospital for Neurology and Neurosurgery, London, UK. 
Genetic conﬁ rmation of the chromosome 17p11·2 duplication was required for Charcot-Marie-Tooth disease 1A, and 
classiﬁ cation as pathologically or clinically deﬁ nite by MRC criteria was required for inclusion body myositis. 
Exclusion criteria were concomitant diseases and safety-related MRI contraindications. Healthy age-matched and sex-
matched controls were also recruited. Assessments were done at baseline and 1 year. The MRI outcomes—fat fraction, 
transverse relaxation time (T2), and magnetisation transfer ratio (MTR)—were analysed during the 12-month follow-
up, by measuring correlation with functionally relevant clinical measures, and for T2 and MTR, sensitivity in muscles 
with fat fraction less than the 95th percentile of the control group. 
Findings Between Jan 19, 2010, and July 7, 2011, we recruited 20 patients with Charcot-Marie-Tooth disease 1A, 20 patients 
with inclusion body myositis, and 29 healthy controls (allocated to one or both of the 20-participant matched-control 
subgroups). Whole muscle fat fraction increased signiﬁ cantly during the 12-month follow-up at calf level (mean absolute 
change 1·2%, 95% CI 0·5–1·9, p=0·002) but not thigh level (0·2%, –0·2 to 0·6, p=0·38) in patients with Charcot-Marie-
Tooth disease 1A, and at calf level (2·6%, 1·3–4·0, p=0·002) and thigh level (3·3%, 1·8–4·9, p=0·0007) in patients with 
inclusion body myositis. Fat fraction correlated with the lower limb components of the inclusion body myositis functional 
rating score (ρ=–0·64, p=0·002) and the Charcot-Marie-Tooth examination score (ρ=0·63, p=0·003). Longitudinal T2 and 
MTR changed consistently with fat fraction but more variably. In muscles with a fat fraction lower than the control group 
95th percentile, T2 was increased in patients compared with controls (regression coeﬃ  cients: inclusion body myositis 
thigh 4·0 ms [SE 0·5], calf 3·5 ms [0·6]; Charcot-Marie-Tooth 1A thigh 1·0 ms [0·3], calf 2·0 ms [0·3]) and MTR reduced 
compared with controls (inclusion body myositis thigh –1·5 percentage units [pu; 0·2], calf –1·1 pu [0·2]; Charcot-Marie-
Tooth 1A thigh –0·3 pu [0·1], calf –0·7 pu [0·1]).
Interpretation MRI outcome measures can monitor intramuscular fat accumulation with high responsiveness, show 
validity by correlation with conventional functional measures, and detect muscle water changes preceding marked 
intramuscular fat accumulation. Conﬁ rmation of our results in further cohorts with these and other muscle-wasting 
disorders would suggest that MRI biomarkers might prove valuable in experimental trials.
Funding Medical Research Council UK.
Copyright © Morrow et al. Open Access article distributed under the terms of CC BY 4.0.
Introduction
In experimental trials, objective, responsive, and valid 
outcome measures are needed to test treatment eﬃ  cacy. 
Neuromuscular disorders are common,1,2 disabling, 
muscle wasting disorders, largely without proven therapy. 
The increasing identiﬁ cation of tractable targets that 
suggest new therapies drives a concomitant need for 
eﬀ ective trial outcome measures.3 Responsive outcome 
measurement in neuromuscular disorders is challenging: 
longitudinal progression is typically slow, so disease 
progression might be masked by age-related changes4 or 
measurement variation, and new therapies are more likely 
to halt or slow progression than reverse established tissue 
damage. This limits outcome measure responsiveness, 
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expressed as the standardised response mean (SRM);5 
SRM is a key determinant of study power, with an inverse 
square relation to required sample size for a stated 
statistical power by Lehr’s formula (panel 1).6 Outcome 
measure validity in terms of correlation against measures 
held to be valid markers of patient function or experience, 
such as relevant neuromuscular disorder functional rating 
scales, must also be established.
The shortcomings of established outcome measures 
were exempliﬁ ed in the UK–Italian ascorbic acid trial6 in 
patients with Charcot-Marie-Tooth disease 1A. The trial 
showed no treatment beneﬁ t, and the placebo group 
natural history data showed only low primary outcome 
measure responsiveness (Charcot-Marie-Tooth disease 
Neuropathy Score SRM=0·19). The study therefore 
might have been underpowered, with the negative result 
suggesting type II error. Increasing group sizes to 
compensate for low responsiveness is challenging in rare 
diseases, and a pressing need exists to identify and 
validate adequately responsive outcome measures for 
neuromuscular disorder clinical trials.7
Acute or early pathological muscle changes, whether 
due to denervation, dystrophy, or inﬂ ammation, typically 
involve tissue water changes, whereas chronic disease is 
characterised by intramuscular fat accumulation. Intra-
muscular fat accumulation is the ﬁ nal common 
pathological pathway for many diﬀ erent primary genetic 
and acquired neuromuscular disorders. MRI Dixon fat-
water imaging,8 which quantiﬁ es tissue fat content on a 
0–100% fat-fraction scale, has been applied to skeletal 
muscle in neuromuscular disorders.9–13 Muscle MRI 
transverse magnetisation relaxation time (T2) and 
magnetisation transfer ratio (MTR) are sensitive to 
changes in muscle water distribution14,15 and lipid content. 
Potential demonstrated in these studies to quantify both 
early or acute and chronic pathology non-invasively and 
objectively suggests these markers might be ideal 
candidate outcome measures for neuromuscular 
disorders. We previously showed their reliability and 
normative age dependencies and sex dependencies in 
healthy volunteers.16 However, before application in trials, 
their validity and responsiveness as disease markers in 
speciﬁ c neuromuscular disorders must be established.
We aimed to test the hypothesis that these indices are 
valid and responsive markers of disease progression using 
clinical, myometric, and MRI assessments at baseline and 
12 months. We studied two deeply phenotyped cohorts 
with Charcot-Marie-Tooth disease 1A and inclusion body 
myositis—representing neurogenic and myopathic, and 
genetic and acquired, conditions with variable disease 
progression rates—and age-matched and sex-matched 
controls. We aimed to examine the validity of MRI-
quantiﬁ ed intramuscular fat accumulation as an outcome 
measure by direct correlation with clinical and myometric 
measures and establish the sensitivity of MRI measures 
to early muscle water changes before substantial 
intramuscular fat accumulation.
Methods
Study design and participants
We did a prospective longitudinal observational study of 
patients attending the inherited neuropathy or muscle 
clinics at the Medical Research Council (MRC) Centre for 
Panel 1: Technical terms
Statistical terms
Responsiveness: the ability of a measure to change over a prespeciﬁ ed timeframe 
(internal responsiveness). External responsiveness represents the extent to which a 
change in a measure relates to corresponding change in a reference measure of clinical or 
health status.
Standardised response mean (SRM): a measure of outcome measure responsiveness 
calculated from natural history or placebo data by dividing the mean change by the 
standard deviation. An SRM of less than 0·2 is thought to have minimal responsiveness 
and an SRM of more than 0·8 is deemed to have large responsiveness. In addition to 
having a high SRM, the measurement must also be expected to respond to the planned 
intervention.
Lehr’s formula: 
A formula to estimate the number of participants in each group for a study with 80% 
power to detect an intergroup diﬀ erence with p<0·05 signiﬁ cance. It is based on SRM and 
eﬀ ect size in terms of reduction in progression versus placebo (E). For example, if a 
clinically signiﬁ cant beneﬁ t is regarded as a 50% reduction in disease progression (E=0·5), 
use of an outcome measure with minimal responsiveness (SRM=0·2), would require 
1600 participants in each study group, whereas an outcome measure with large 
responsiveness (SRM=0·8) would require 100 participants in each group.
Validity: measured by comparing the results of a measurement to the results of a gold 
standard test. For an outcome measure, validity here refers to correspondence with 
clinical measures of patient function, considered along with mortality as possible “true 
outcome measures” in a clinical trial.
MRI terms
Fat fraction: the proportion of water (W) to fat (F) signal originating in the measurement 
volume reported as a percentage.
3-point-Dixon fat water separation: an MRI technique yielding separate fat-only and 
water-only images 
Remaining muscle area: deﬁ ned here as the cross-sectional area of muscle tissue within 
the muscle fascial boundary (CSA) not replaced by fat.
Transverse relaxation time (T2): a key source of MRI contrast representing changes in 
molecular mobility, commonly interpreted in terms of tissue water or lipid distribution 
changes.  
Magnetisation transfer ratio (MTR): an MRI measure being the signal intensity ratio 
between a control image and one made sensitive to changes in the relative population of 
free water in tissue and the rate of magnetisation exchange with other proton pools.
Fat fraction= F
(F+W) 
× 100%
n=
(E·SRM)2  
16
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Neuromuscular Diseases at the National Hospital for 
Neurology and Neurosurgery, London, UK (ﬁ gure 1). 
Inclusion criteria were genetic conﬁ rmation of the 
chromosome 17p11·2 duplication for patients with 
Charcot-Marie-Tooth disease 1A, and classiﬁ cation as 
pathologically or clinically deﬁ nite by MRC criteria17 for 
patients with inclusion body myositis, and being aged 
17 years or older (as the study was based in an adult 
hospital). Exclusion criteria were concomitant diseases 
and safety-related MRI contraindications (appendix). 
Patients meeting these inclusion criteria and attending 
the clinics were invited to participate. Healthy participants 
were enrolled as controls in two overlapping subgroups 
comprising 20 participants each, one matched for age, 
sex, weight, and body-mass index distribution to the 
Charcot-Marie-Tooth disease 1A group and one matched 
for the same variables to the inclusion body myositis 
group. Controls were recruited in the ﬁ rst instance from 
spouses, friends, and relatives of the patients, who 
underwent assessments on the same day as the respective 
patient (relatives of patients with Charcot-Marie-Tooth 
disease 1A were included only if genetic testing was 
negative). Because patients with inclusion body myositis 
group are older men (usually older than 45 years),18 the 
controls recruited were not well matched to those 
patients, and the youngest six individuals in the inclusion 
body myositis control subgroup were replaced by six 
healthy individuals recruited from hospital and research 
staﬀ  whose ages fell within the speciﬁ c demographics of 
the inclusion body myositis group. Clinical assessments 
and myometry were done at the MRC Centre for 
Neuromuscular Diseases, UCL Institute of Neurology, 
UK. MRI was done at the National Hospital for Neurology 
and Neurosurgery, London, UK. Cross-sectional MRI data 
from all of the control participants, combined with data 
from other participants scanned using the same MRI 
protocol, have been reported previously.16
The study was approved by the local ethics committee and 
all participants provided written informed consent at 
enrolment. 
Procedures
The following assessments were done in all patients: 
medical history, neurological examination, bedside 
20 patients with CMT1A enrolled
 
29 healthy controls enrolled
 
20 patients with IBM enrolled
 
20 controls matched to CMT1A* 
 
 
20 controls matched to IBM*
 
 
Cross-sectional analysis
2 patients with CMT1A
 dropped out 
 1 ankle surgery
  1 unable to contact
2 patients with IBM dropped
 out (no longer able to travel) 
18 patients with CMT1A disease had 
 12-month follow-up assessments 
 (MRI, clinical assessment, and 
 myometry), and were included in 
 the longitudinal analysis
18 controls matched to patients with 
 CMT1A had 12-month follow-up 
 assessments (MRI, clinical 
 assessment, and myometry), 
 and were included in the 
 longitudinal analysis
19 controls matched to IBM had 
 12-month follow-up assessments 
 (MRI, clinical assessment, and
 myometry), and were included in 
 the longitudinal analysis
18 patients  with IBM had 12-month 
 follow-up assessments (MRI,
 clinical assessment, and 
 myometry), and were included in 
 the longitudinal analysis
Baseline assessments: MRI, clinical assessment, myometry
2 controls dropped out
 (attended with patients)†
1 control dropped out
 (attended with patient)†
26 patients with CMT1A were
 screened for eligibility
31 controls were
 screened for eligibility
32 patients with IBM were
 screened for eligibility
6 ineligible
 1 contraindication to MRI
 2 exclusion criteria comorbidity
 3 refused to participate
2 ineligible (contraindication 
 to MRI)
12 ineligible 
 3 contraindication to MRI
 7 exclusion criteria comorbidity
 2 were unable to travel for 
 assessments
Figure 1: Flow chart of patient assessments and dropout
CMT1A=Charcot-Marie-Tooth 1A. IBM=inclusion body myositis. *11 controls were common to both disease control groups. †Three controls dropped out because they had undertaken baseline 
assessments accompanying patients who dropped out before repeat assessments. 
See Online for appendix
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strength examination using MRC grading (appendix), and 
SF-36 quality of life questionnaire.19 Patients with Charcot-
Marie-Tooth disease 1A were assessed with the Charcot-
Marie-Tooth examination score (version 2; CMTES),20 a 
28-point score based on signs and symptoms where 28 is 
very severely aﬀ ected. Patients with inclusion body 
myositis were assessed with the inclusion body myositis 
functional rating scale (IBMFRS), a 40-point score where 
0 is most functionally impaired.21 Patients and controls 
underwent detailed lower limb myometry on a HUMAC 
NORM dynamometer (CSMi, MA, USA; see appendix for 
full assessment protocol).
Participants were examined lying feet-ﬁ rst and supine in 
a 3T MRI scanner (TIM Trio, Siemens, Erlangen, 
Germany). The quantitative MRC Centre MRI protocol 
was developed and included fat fraction, transverse 
relaxation time (T2), and magnetisation transfer ratio 
(MTR) measurement. These parameters were analysed 
during the 12-month follow-up, by measuring correlation 
with functionally relevant clinical measures, and for T2 
and MTR, sensitivity in muscles with fat fraction less than 
the 95th percentile of the control group. The following 
measurements were done: 3-point-Dixon fat-fraction 
quantiﬁ cation resulting in fat-fraction maps expressed 
as percentage fat (0–100%),8 non-fat-suppressed T2 
measurement by dual-contrast turbo-spin-echo imaging, 
and MTR imaging requiring two 3D-FLASH images with 
and without a magnetisation transfer pre-pulse with 
radiofrequency ﬁ eld (B1) non-uniformity correction 
resulting in MTR maps with values expressed by 
convention in percentage units (0–100 pu).22 Sequence 
details and variables are listed in the appendix; the total 
acquisition time per participant per visit was about 35 min.
 Statistical analysis
The number of patients recruited from each of the 
disease groups was based pragmatically on the number 
of patients known to have the disease of interest and 
eligible for enrolment. 20 patients in each disease group 
were deemed suﬃ  cient to identify trends in MRI 
variables and provide data useful to inform statistical 
power estimates in future studies.
A single observer (a radiologist with 4 years of specialist 
experience in neuromuscular imaging) masked to all 
clinical details including diagnosis deﬁ ned whole muscle 
and small regions of interest (ROIs) for each participant on 
single slices (appendix) for all muscles at mid-thigh and 
mid-calf levels from an unprocessed Dixon acquisition 
(echo time=3·45 ms) using ITK-SNAP software (ﬁ gure 2).23
The small ROIs were transferred to the co-registered fat 
fraction, T2, and MTR variable maps. For each muscle, 
mean T2, mean fat fraction, and mean MTR were recorded 
from the small ROIs, and mean fat fraction and muscle 
cross-sectional area (CSA) were recorded from the whole 
muscle ROIs. A systematic bias was noted in T2 
measurements after a routine scanner software upgrade 
SM ST BF
TA
PL
SoMG
LG
TP
VMSa
G AM
RF
VL
VI
A B
C D
Control CMT1A IBM
Control CMT1A IBMControl CMT1A IBM
0%
100%
0 ms
200 ms
0 pu
50 pu
Figure 2: Regions of interest and sample axial images of left lower limb
In each panel the upper row shows the mid-thigh level and the lower row shows the mid-calf level. (A) Unprocessed Dixon sequence (echo time=3·45 ms) in a healthy 
control (left), with overlaid whole muscle regions of interest (centre) and small regions of interest (right) for the same participant. (B) Fat-fraction map of a 
participant from each group. (C) Transverse relaxation time (T2) map of a participant from each group. (D) Magnetisation transfer ratio map of a participant from 
each group. RF=rectus femoris. VL=vastus lateralis. VM=vastus medialis. VI=vastus intermedius. Sa=sartorius. G=gracilis. AM=adductor magnus. 
SM=semimembranosus. ST=semitendinosus. BF=biceps femoris. TA=tibialis anterior group. MG=medial head of gastrocnemius. So=soleus. TP=tibialis posterior. 
PL=peroneus longus. LG=lateral head of gastrocnemius. pu=percentage units.
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necessitating a minor correction to post-upgrade values 
(appendix). For each participant, individual muscle values 
were combined into a summary measure calculated for 
each variable for all muscles (left and right limb) at thigh 
level and at calf level, and for relevant functional muscle 
groups (quadriceps, hamstrings, anterior tibial compart-
ment, and triceps surae) for left and right limbs separately. 
Summary measures were calculated for small ROIs as the 
mean of the individual muscle values, and for whole muscle 
ROIs as the mean of individual muscle values weighted by 
cross-sectional area. To assess early pathological changes in 
patients’ muscles for which intramuscular fat accumulation 
lay within the normal healthy range, additional analyses 
included only muscles with mean fat fraction less than the 
95th percentile of the healthy control data for thigh and calf 
muscles separately. As a measure of the functional muscle 
CSA, the metric remaining muscle area was calculated with 
the following equation, where CSA and fat fraction refer to 
the whole muscle ROI values:
Charcot-Marie-
Tooth 1A group
Control group for 
Charcot-Marie-
Tooth 1A disease
p value Inclusion body 
myositis group
Control group for 
inclusion body 
myositis
p value
Demographics
Sex
Male 11 11 1 16 12 0·17 
Female 9 9 1 4 8 0·17 
Age (years) 42·8 (13·9) 45·8 (14·2) 0·51 66·7 (8·9) 61·8 (10·3) 0·12
Height (cm) 167 (12) 171 (11) 0·34 175 (8) 171 (10) 0·28
Weight (kg) 70 (16) 75 (19) 0·44 84 (16) 77 (19) 0·22
Body-mass index 25·1 (4·6) 25·4 (4·9) 0·84 27·4 (4·0) 26·0 (4·6) 0·30
Clinical parameters
Age of onset (years) 6·0 (4·4) NA NA 59·0 (8·5) NA NA
Disease duration (years) 35·8 (17·5) NA NA 7·7 (3·1) NA NA
CMTSS (0–12)* 3·1 (2·0) NA NA NA NA NA
CMTES (0–28)* 8·0 (5·1) NA NA NA NA NA
MRC-LL (0–110)* 95·4 (15·4) NA NA 93·4 (15·7) NA NA
SF36 (0–100%) 73·9% (15·2) NA NA 61·5% (15·3) NA NA
SF36-PF (0–100%) 65·3% (23·2) NA NA 39·5% (19·1) NA NA
IBMFRS (0–40)* NA NA NA 27·6 (5·4) NA NA
Myometric measures
Knee extension (Nm) 93·6 (44·1) 134·9 (43·5) 0·005 26·8 (26·0) 119·9 (43·0) <0·0001
Knee ﬂ exion (Nm) 47·2 (20·1) 66·1 (20·4) 0·006 35·3 (19·9) 60·6 (20·1) <0·0001
Ankle plantarﬂ exion (Nm) 26·0 (14·3) 62·0 (19·1) <0·0001 29·6 (15·7) 51·6 (18·4) <0·0001
Ankle dorsiﬂ exion (Nm) 10·8 (7·5) 30·0 (9·8) <0·0001 13·2 (10·8) 28 (10·6) <0·0001
Thigh MRI
Fat fraction (%) 3·7% (6·8) 1·7% (1·3) 0·23 26·6% (15·5) 2·0% (1·2) <0·0001
T2 (ms) 45·7 (9·1) 41·8 (3·1) 0·08 83·5 (17·7) 43·1 (2·5) <0·0001
MTR (pu) 30·8 (3·0) 32·0 (0·8) 0·09 22·9 (5·0) 31·6 (0·7) <0·0001
Fat fraction whole (%) 5·8% (8·5) 3·3% (1·8) 0·23 27·5% (15·7) 4·0% (1·6) <0·0001
CSA (cm2) 201 (53) 219 (56) 0·31 169 (46) 212 (51) 0·009
Calf MRI
Fat fraction (%) 15·8% (25·5) 1·6% (1·0) 0·02 18·0% (13·2) 2·0% (0·9) <0·0001
T2 (ms) 59·7 (29·3) 40·2 (3·6) 0·005 71·1 (21·4) 41·9 (3·8) <0·0001
MTR (pu) 26·1 (9·0) 32·1 (1·0) 0·007 23·7 (5·7) 31·6 (0·9) <0·0001
Fat fraction whole (%) 15·5% (24·0) 2·7% (1·5) 0·03 19·2% (13·7) 3·5% (1·3) <0·0001
CSA (cm2) 100 (26) 123 (27) 0·01 112 (26) 120 (31) 0·39
Data are presented mean (SD), unless otherwise indicated. MRI values are all-muscle region-of-interest means at the respective anatomical levels. For sex, the p value is for the 
Pearson χ² test and for all other variables, the p value is for the two-tailed test. NA=not applicable. CMTSS=Charcot-Marie-Tooth symptom score. CMTES=Charcot-Marie-Tooth 
examination score. MRC-LL=Medical Research Council lower limb score. SF36=Short-Form 36 Quality of Life Score. PF=physical function domain. IBMFRS=inclusion body 
myositis functional rating scale. MTR=magnetisation transfer ratio. CSA=cross-sectional area. pu=percentage units *Controls had no neuromuscular symptoms and were 
normal on neurological examination so all scored 0 on CMTES and CMTSS and attained the maximum score on IBMFRS (40) and MRC-LL (110). 
Table 1: Baseline characteristics
Remaining muscle area = CSA × (100 – fat fraction) 
100%
Articles
70 www.thelancet.com/neurology   Vol 15   January 2016
Longitudinal changes were quantiﬁ ed on a muscle-
by-muscle, variable-by-variable basis, and combined in 
the same way as for cross-sectional data to create 
separate all-muscle summary variables at thigh level 
and calf level.
Statistical analyses were done with IBM-SPSS 
Statistics (version 20). At baseline, cross-sectional 
diﬀ erences between each patient group and their 
respective matched controls were assessed for each 
measure using two-tailed t tests. Correlations between 
measures at baseline were assessed with Pearson or 
Spearman correlation as appropriate. Missing data were 
excluded from the analysis. Diﬀ erences between 
baseline and follow-up values for each measure for each 
patient group were assessed with paired t tests, and two-
tailed t tests compared absolute change over 12 months 
between the patient and respective matched-control 
groups. Multivariate linear regressions were done to 
assess the dependence of T2 and MTR upon disease 
group membership in muscles without substantial 
intramuscular fat accumulation (deﬁ ned as fat fraction 
less than the control group 95th percentile), while 
adjusting for the inﬂ uence of residual fat fraction as a 
covariate.
Figure 3: Cross-sectional data
(A) Overall fat fraction is signiﬁ cantly increased at both thigh and calf level in patients with inclusion body myositis and at calf level in patients with CMT1A compared 
with matched controls. Boxes represent median and IQR, whiskers show range, and ﬁ lled circles are outliers. (B) Combination of all muscles without substantial 
intramuscular fat accumulation shows that muscle T2 is increased and MTR is reduced in muscles from patients with IBM, showing early pathological changes. Similar 
signiﬁ cant diﬀ erences of lower magnitude were also identiﬁ ed in CMT1A. (C) Fat-fraction maps of the right thigh in a healthy control and a patient with IBM. In the 
patient, fatty inﬁ ltration of muscles is greatest in the quadriceps (red region of interest), which also has a reduced CSA. The mean fat fraction and CSA can be combined 
to calculate the composite MRI metric, RMA. (D) RMA of quadriceps muscle showed signiﬁ cant correlation with knee extension strength in patients with IBM, CMT1A, 
and controls. Equivalent graphs of other movements are shown in the appendix. (E) Strong correlations were observed between mean thigh fat fraction and IBMFRS-LL 
(r=–0·64) for patients with IBM. FF=fat fraction. IBM=inclusion body myositis. CMT1A=Charcot-Marie-Tooth 1A. T2=transverse relaxation time. MTR=magnetisation 
transfer ratio. CSA=cross-sectional area. RMA=remaining muscle area. IBMFRS-LL=inclusion body myositis functional rating score lower limb. 
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Role of the funding source
The study funders had no role in the study design, data 
collection, data analysis, data interpretation, or writing 
of the report. The corresponding author and all 
coauthors had full access to all the data in the study and 
had ﬁ nal responsibility for the decision to submit for 
publication.
Results 
Between Jan 19, 2010, and July 7, 2011, we recruited 
20 patients with Charcot-Marie-Tooth disease 1A, 
20 patients with inclusion body myositis, and 29 healthy 
controls allocated to one or both of the 20-participant 
control subgroups (ﬁ gure 1). Age, sex, height, and weight 
were similar between the two patient groups and their 
respective matched controls (table 1). In both patient 
groups, baseline myometric muscle strength was 
signiﬁ cantly reduced in all muscle groups compared 
with their matched controls (table 1, appendix). At 
baseline, patients with inclusion body myositis had 
signiﬁ cantly higher all-muscle fat fraction and T2, and 
lower all-muscle MTR, at both thigh level and calf level 
than matched controls (table 1, ﬁ gure 3). The all-muscle 
CSA in the inclusion body myositis group was lower than 
that of matched controls at thigh level but not at calf level 
(table 1). Patients in the Charcot-Marie-Tooth disease 1A 
group had signiﬁ cantly higher all-muscle fat fraction and 
T2 and lower MTR than matched controls at calf level but 
not at thigh level, whereas their all-muscle CSA was 
lower than for the controls at calf level but not at thigh 
level (table 1, ﬁ gure 3).
Repeat assessments (table 2) were done after a mean of 
12·4 months (SD 1·0). In the inclusion body myositis 
group, the MRC lower limb score, inclusion body 
myositis functional rating scale (IBMFRS), and overall 
myometric knee extension strength deteriorated 
signiﬁ cantly during follow-up. In the Charcot-Marie-
Tooth disease 1A group, none of the clinical measures 
changed signiﬁ cantly. Although myometric ankle 
dorsiﬂ exion strength showed a signiﬁ cant increase 
Inclusion body myositis group 
(baseline vs 12-month follow-
up)
Control group for inclusion 
body myositis (baseline vs 
12-month follow-up)
Paired t test 
p value (12-month 
follow-up vs 
baseline in patient 
group)
Two-tailed p 
value (patient 
vs matched 
control over 
12 month 
follow-up) 
Standardised 
response 
mean
Overall clinical measures
MRC-LL*† –3·4 (5·6; 0·6 to 6·2) NA 0·02 NA 0·63
SF36 (%) –1·1% (7·0; –2·7 to 4·8) NA 0·55 NA 0·16
SF36-PF (%) –4·1% (18·5; –13·9 to 5·8) NA 0·39 NA 0·22
IBMFRS*† –2·8 (2·9; 1·3 to 4·2) NA 0·0008 NA 0·97
Thigh myometry
Knee extension (Nm) –6·0 (5·2; –8·4 to –3·6) –4·2 (11·4; –9·5 to 1·1) 0·002 0·55 –1·15
Knee ﬂ exion (Nm) –1·7 (4·3; –3·7 to 0·2) 2·9 (7·1; –0·4 to 6·2) 0·08 0·02 –0·40
Calf myometry
Ankle plantarﬂ exion (Nm) –0·7 (3·9; –2·5 to 1·1) 5·6 (14·6; –1·2 to 12·4) 0·42 0·09 –0·19
Ankle dorsiﬂ exion (Nm) –0·4 (4·2; –2·4 to 1·5) 2·0; 5·3 (–0·4 to 4·4) 0·65 0·14 –0·10
Thigh MRI
Fat fraction (%)† 3·3% (4·0; 1·4 to 5·2) 0·1% (0·4; –0·3 to 0·1) 0·005 0·001 0·83
T2 (ms) 2·6 (4·2; 0·5 to 4·7) 0·5 (1·6; –0·3 to 1·3) 0·03 0·07 0·62
MTR (pu) –0·9 (1·6; –1·7 to 0·0) 0·0 (0·5; –0·2 to 0·2) 0·06 0·06 –0·54
Fat-fraction whole (%)† 3·3% (3·2; 1·8 to 4·9) 0·2% (0·8; –0·2 to 0·6) 0·0007 0·0004 1·06
CSA (% change) –2·7% (7·9; –6·5 to 1·1) 0·2 (5·7; –2·5 to 2·9) 0·08 0·23 –0·34
Calf MRI
Fat fraction (%)† 2·6% (2·7; 1·1 to 4·1) 0·0 (0·4; –0·2 to 0·2) 0·004 0·0007 0·97
T2 (ms)† 4·5 (3·7; 2·6 to 6·4) 0·0 (1·5; –0·7 to 0·7) 0·0005 <0·0001 1·21
MTR (pu)† –0·7 (0·7; –1·1 to –0·3) 0·2 (0·8; –0·2 to 0·6) 0·004 0·003 –0·99
Fat-fraction whole (%)† 2·6% (2·4; 1·3 to 4·0) 0·1% (0·4; –0·1 to 0·3) 0·002 0·0006 1·07
CSA (% change) –2·5% (3·9; –4·4 to –0·6) 0·1% (5·0; –2·3 to 2·5) 0·01 0·11 –0·63
Data are mean (SD; 95% CI), unless otherwise indicated. Fat-fraction whole and CSA are from whole muscle regions of interest, whereas fat fraction, T2, and MTR are from 
small regions of interest. NA=not applicable. MRC-LL=Medical Research Council lower limb score. SF36=Short-Form 36 Quality of Life Score. PF=physical function domain. 
IBMFRS=inclusion body myositis functional rating scale. MTR=magnetisation transfer ratio. CSA=cross-sectional area. pu=percentage units. *Controls had no neuromuscular 
symptoms and were normal on neurological examination so attained the maximum score on IBMFRS (40) and MRC-LL (110), and they did not have quality of life 
assessments. †Follow-up value is signiﬁ cantly diﬀ erent from baseline and change is signiﬁ cantly diﬀ erent from change in controls (both paired t test and two-tailed t test are 
signiﬁ cant). 
Table 2: Change in all-muscle MRI and clinical measures between baseline and 12-month follow-up in patients with inclusion body myositis
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(p=0·049) compared with baseline, this was not 
signiﬁ cant (p=0·24) compared with the change in 
matched controls.
Quantitative MRI values for individual muscles are 
given in the appendix. Strong correlations were noted 
between the three quantitative MRI measures (fat 
fraction, MTR, and T2) of individual muscles (all r>0·89, 
p<0·0001, appendix).
In patients with inclusion body myositis, at 12-month 
follow-up all-muscle thigh-level and calf-level fat fraction 
(ﬁ gure 4), for both small and whole muscle ROIs, and 
calf muscle T2 had increased signiﬁ cantly from 
baseline, whereas calf muscle MTR signiﬁ cantly 
decreased (table 2). All-muscle CSA signiﬁ cantly 
decreased compared with baseline (p=0·01) at calf level 
but not at thigh level (p=0·08). In patients with Charcot-
Marie-Tooth disease 1A, calf level all-muscle fat fraction 
increased signiﬁ cantly during the 12-month follow-up 
(ﬁ gure 4), whereas T2, MTR, and muscle CSA did not 
change signiﬁ cantly (table 3), nor did any MRI measures 
at thigh level. In the control groups, no signiﬁ cant 
12-month changes in fat fraction, T2, or MTR were 
reported at either level.
For the 29 control participants, the fat-fraction 
95th percentiles were 4·8% for thigh muscles and 4·7% 
for calf-level muscles, deﬁ ning the upper thresholds for 
intramuscular fat accumulation in these healthy controls. 
On regression analyses done separately for the inclusion 
body myositis and Charcot-Marie-Tooth disease 1A 
groups, combined with their respective controls, 
including only data from all individual patient and control 
muscles with fat fraction lower than these thresholds, T2 
and MTR remained signiﬁ cantly dependent on fat 
fraction (appendix). However, the dependencies for 
control versus disease status were also signiﬁ cant in each 
case (appendix), with increased T2 (thigh 4·0 ms [SE 0·5], 
calf 3·5 ms [0·6]) and reduced MTR (thigh –1·5 pu [0·2], 
calf –1·1 pu [0·2]) independent of fat fraction in this 
regression model, in patients with inclusion body 
myositis versus matched controls. Smaller but signiﬁ cant 
fat-fraction-adjusted dependencies were also reported in 
patients with Charcot-Marie-Tooth disease 1A versus 
matched-controls, especially at calf level (T2 thigh 1·0 ms 
[0·3], calf 2·0 ms [0·3]; MTR thigh –0·3 pu [0·1], calf 
–0·7 pu [0·1]). The distribution of T2 and MTR values 
in muscles without substantial intramuscular fat 
accumulation in patients with inclusion body myositis is 
shown (ﬁ gure 3).
In all groups, for all movements assessed, muscle 
strength correlated strongly with the corresponding 
muscle group total CSA (appendix). In regions where 
patients’ fat fraction was signiﬁ cantly increased 
(inclusion body myositis thigh and calf level, 
Charcot-Marie-Tooth 1A calf level), whole muscle fat-
fraction correlated negatively with muscle strength 
(appendix). The combined variable remaining muscle 
area correlated more strongly with strength than with 
either CSA or fat fraction separately (ﬁ gure 3, appendix).
Signiﬁ cant correlations were also noted between 
summary clinical measures and all-muscle fat fraction 
measurements. In patients with inclusion body myositis, 
all-muscle thigh-level fat fraction correlated with disease 
duration (ρ=0·50, p=0·03, appendix), IBMFRS (ρ=–0·53, 
p=0·02), IBMFRS lower limb components (ρ=–0·64, 
p=0·002, ﬁ gure 3), total MRC lower limb score (ρ=–0·60, 
p=0·005), and the physical function domain of the 
Figure 4: Longitudinal data
Boxes represent median and IQR, whiskers show range and ﬁ lled circles are outliers. (A) Fat-fraction maps of the right calf at baseline and after 1 year are shown for control participants and patients 
with CMT1A and IBM. Minimal change is seen in the mean overall fat fraction in the control, but an increase of 2·0% is shown in the patient with CMT1A and of 7·9% in the patient with IBM.  (B) Group 
comparison against matched controls shows signiﬁ cant increases in overall mean fat fraction in patients with IBM at thigh and calf level and in patients with CMT1A at calf level. (C) Change in 
quadriceps RMA correlated with change in quadriceps strength over 12 months in patients with IBM for both left and right legs. No signiﬁ cant correlations were seen between 1-year changes in 
myometric and MRI measures in the CMT1A group. CMT1A=Charcot-Marie-Tooth 1A. IBM=inclusion body myositis. FF=fat fraction. RMA=remaining muscle area.
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Short-Form 36 Quality of Life Score (SF36-PF; ρ=–0·60, 
p=0·007). Overall SF36 (ρ=–0·11, p=0·66) and age 
(ρ=0·14, p=0·55) were not signiﬁ cantly correlated with 
fat fraction. In patients with Charcot-Marie-Tooth 1A 
disease, all-muscle calf-level fat fraction correlated with 
disease duration (ρ=0·89, p<0·0001, appendix), age 
(ρ=0·84, p<0·0001), CMTES (ρ=0·63, p=0·003, 
appendix), lower limb motor component of the CMTES 
(ρ=0·77, p<0·0001), and reduced total MRC lower limb 
score (ρ=–0·76, p<0·0001). The correlation between all-
muscle calf fat fraction and total SF36 score was not 
signiﬁ cant (ρ=–0·34, p=0·18); however, the correlation 
with the SF36-PF was signiﬁ cant (ρ=–0·63, p=0·007).
Correlations between the change in clinical variables and 
the change in MRI variables were not signiﬁ cant in the 
Charcot-Marie-Tooth group. However, in patients with 
inclusion body myositis, the change in myometric strength 
of knee extension correlated with change in several MRI 
variables, including quadriceps remaining muscle area 
(right r=0·66, p=0·005, left r=0·81, p=0·0001; ﬁ gure 4).
The highest SRMs, greater than 1, were for whole 
muscle fat fraction at thigh and calf level, and T2 at calf 
level, whereas no clinical variables had an SRM greater 
than 1 (table 2). In the CMT group, signiﬁ cant 12-month 
change occurred only in whole muscle fat fraction at calf 
level, with an SRM of 0·83 (table 3).
Discussion
In this study, quantitative MRI measures changed 
signiﬁ cantly during the 12-month follow-up in calf 
muscles of patients with Charcot-Marie-Tooth disease 1A 
and both thigh and calf muscles in patients with 
inclusion body myositis. MRI-measured fat fraction 
showed greater responsiveness (higher SRM) than 
clinical or myometric measures. Fat fraction correlated 
with strength and function. Even after adjustment for fat 
fraction, T2 was increased and MTR was reduced in 
muscles without substantial intramuscular fat 
accumulation in both patient groups compared with 
controls, suggesting sensitivity to early and potentially 
Charcot-Marie-Tooth 1A 
group (baseline vs 12-month 
follow-up) 
Control group for Charcot-
Marie-Tooth 1A disease
Paired t test 
p value 
(12-month 
follow-up vs 
baseline in 
patient group) 
Two-tailed 
p value 
(patient vs 
matched 
control over 
12-month 
follow-up) 
Standardised 
response mean
Overall clinical measures
MRC-LL* –0·4 (3·8; –1·5 to 2·3) NA 0·65 NA –0·11
SF36 (%) –2·5 (15·2; –5·3 to 10·3) NA 0·51 NA –0·16
SF36-PF (%) –0·9 (12·3; –5·4 to 7·2) NA 0·77 NA –0·08
CMTES* –0·3 (1·3; –0·9 to 0·4) NA 0·37 NA –0·23
Thigh myometry
Knee extension (Nm) 1·0 (8·1; –2·8 to 4·8) –5·2 (10·2; –9·9 to –0·4) 0·57 0·06 0·12
Knee ﬂ exion (Nm) 2·5 (6·8; –0·7 to 5·8) 1·7 (7·6; –1·7 to 5·2) 0·15 0·75 0·37
Calf myometry
Ankle plantarﬂ exion (Nm) 3·8 (7·6; 0·0 to 7·4) 2·1 (10·8; –2·9 to 7·1) 0·06 0·59 0·51
Ankle dorsiﬂ exion (Nm) 2·1 (4·0; 0·2 to 4·0) 0·5 (3·8; –1·3 to 2·2) 0·05 0·24 0·51
Thigh MRI
Fat fraction (%) 0·4 (1·0; –0·1 to 0·9) 0·0 (0·3; –0·1 to 0·1) 0·15 0·12 0·36
T2 (ms) 1·3 (1·5; 0·6 to 2·1) 0·6 (1·6; –0·2 to 1·4) 0·003 0·21 0·86
MTR (pu) 0·0 (0·7; –0·3 to 0·3) –0·1 (0·3; –0·3 to 0·1) 0·96 0·55 –0·01
Fat-fraction whole (%) 0·2 (0·8; –0·2 to 0·6) 0·2 (0·8; –0·2 to 0·6) 0·38 0·97 0·22
CSA (% change) –0·6 (5·3; –3·1 to 1·9) –0·7 (7·2; –4·0 to 2·6) 0·62 0·96 –0·12
Calf MRI
Fat fraction (%) 1·1 (2·4; 0·2 to 2·2) 0·0 (0·4; –0·2 to 0·2) 0·07 0·07 0·46
T2 (ms) 1·4 (2·6; 0·0 to 2·6) 0·3 (1·1; –0·2 to 0·9) 0·05 0·13 0·54
MTR (pu) –0·2 (0·6; –0·5 to 0·1) 0·0 (0·7; –0·3 to 0·4) 0·30 0·28 –0·34
Fat-fraction whole (%)† 1·2 (1·5; 0·5 to 1·9) 0·2 (0·4; 0·0 to 0·4) 0·002 0·008 0·83
CSA (% change) 0·6 (6·6; –2·5 to 3·8) 0·0 (4·4; –2·0 to 2·0) 0·67 0·74 0·10
Data are mean (SD; 95% CI), unless otherwise indicated. Fat fraction whole and CSA are from whole muscle regions of interest, whereas fat fraction, T2, and MTR are from small 
regions of interest. NA=not applicable. MRC-LL=Medical Research Council lower limb score. SF36=Short-Form 36 Quality of Life Score. PF=physical function domain. 
CMTES=Charcot-Marie-Tooth 1A examination score. T2=transverse relaxation time. MTR=magnetisation transfer ratio. CSA=cross-sectional area. *Controls had no 
neuromuscular symptoms and were normal on neurological examination so scored 0 on CMTES and attained the maximum score on MRC-LL (110), and they did not have quality 
of life tests. †Follow-up value is signiﬁ cantly diﬀ erent from baseline and is signiﬁ cantly diﬀ erent from change in controls (both paired t test and two-tailed t test are signiﬁ cant). 
Table 3: Change in all-muscle MRI and clinical measures between baseline and 12-month follow-up in patients with Charcot-Marie-Tooth 1A disease
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reversible changes in muscle water distribution. MRI 
therefore provides responsive outcome measures with 
validity suitable for application in future clinical trials of 
neuromuscular disorders.
The development of responsive outcome measures has 
proven especially diﬃ  cult so far in neuromuscular 
disorders such as Charcot-Marie-Tooth 1A. The CMTNS 
was selected at the 136th European Neuromuscular 
Centre workshop24 as the most appropriate primary 
outcome measure for Charcot-Marie-Tooth 1A trials and 
was used in the ascorbic acid trials in adults.6,25,26 The 
SRM of the CMTNS and other outcome measures in the 
largest of these trials6 together with 5-year natural history 
data4 are shown in the appendix. On average, a 0·3 points 
per year increase in CMTNS is reported, resulting in 
minimal responsiveness over 2 years and small 
responsiveness over 5 years. Neurophysiology showed 
either no signiﬁ cant change from baseline6 or change no 
greater than seen in controls4 so seems unsuitable as an 
outcome measure. Ankle dorsiﬂ exion showed mild 
responsiveness during 2 years using a custom built frame 
but no responsiveness during 5 years with hand-held 
myometry and in our study an apparent improvement in 
Charcot-Marie-Tooth 1A and controls was probably due to 
a learning eﬀ ect. By marked contrast, in this study, calf-
level MRI-quantiﬁ ed fat fraction showed large 
responsiveness (SRM=0·83) with a highly signiﬁ cant 
(p=0·002) increase in fat fraction at 12 months. This 
ﬁ nding has important implications for future trial design. 
For a hypothetical Charcot- Marie -Tooth 1A treatment trial 
powered to detect a 50% reduction in disease progression 
during a 1-year period with 80% power at p<0·05 
signiﬁ cance, the number of patients needed in active and 
placebo groups27 would be roughly 93 with calf muscle 
MRI-determined fat fraction as the primary outcome 
measure, as opposed to 7700 patients for the equivalent 
statistical power with CMTNS as the outcome. MRI-
quantiﬁ ed calf muscle fat fraction is therefore the most 
responsive outcome measure proposed so far in 
Charcot-Marie-Tooth 1A.
Progression in inclusion body myositis is somewhat 
faster than in Charcot-Marie-Tooth 1A, with a 10-year 
median interval between symptom onset and signiﬁ cant 
disability.28 By contrast with the Charcot-Marie-Tooth 1A 
group, in the inclusion body myositis group, signiﬁ cant 
change during the 12-month follow-up was detected in 
IBMFRS, knee extension strength, MRC scores, 
myometry-measured knee extension, and many MRI 
measures. However, only MRI measure SRMs exceeded 
1. Furthermore, quadriceps remaining muscle area 
correlated with change in knee extension strength 
(ﬁ gure 4), showing for the ﬁ rst time a direct link 
between MRI-detected change and functional deﬁ cit. 
Thus, although MRI detected signiﬁ cant fat fraction 
progression during 12 months in both disease groups, 
in the more slowly progressive Charcot-Marie-Tooth 1A, 
calf-level MRI-measured fat fraction was the only 
measure to change signiﬁ cantly. In the more progressive 
inclusion body myositis, signiﬁ cant changes in several 
MRI, and some clinical and myometric, measures 
showed that the MRI indices were more responsive.
Additionally to responsiveness, outcome measures 
should show validity through correlation to relevant 
patient function. We showed strong clinical-MRI 
correlations for both overall participant and individual 
muscle measures. In both Charcot-Marie-Tooth 1A and 
inclusion body myositis, strong correlations exist 
between overall MRI measures and quality of life 
indices, functional or composite scales (IBMFRS and 
CMTES), and bedside strength examination, consistent 
with previous research.9,13,29,30 At the individual muscle 
level, the intuitively expected correlation between CSA 
and strength in healthy controls was shown here, similar 
to a previous study.31 In both sets of patients, negative 
correlation between strength and fat fraction was noted, 
also shown previously in myotonic dystrophy for ankle 
dorsiﬂ exion9 and in this study for both ankle and knee 
movements in both diseases. Muscle CSA and fat 
inﬁ ltration, when combined as remaining muscle area, 
correlated most strongly with strength. This might be 
superior to simple T1 and T2 measurements, which 
failed to show a correlation with strength in a study of 
patients with poliomyelitis.32 Thus, MRI provides indices 
of chronic muscle pathology that are highly correlated to 
muscle strength, but independent of participant eﬀ ort or 
operator involvement, which lead to poor test-retest and 
interobserver reliability33 of direct muscle strength 
measures. MRI, therefore, provides a valid, reliable16 
surrogate measure of muscle strength.
Because the T2 of fat greatly exceeds that of muscle 
water, and vice versa for MTR, T2 and MTR are aﬀ ected 
by both fat fraction (exempliﬁ ed by the strong inter-MRI 
variable correlations) and potentially independent early 
tissue water distribution changes. For this reason, T2 
obtained in this manner is referred to as total T2 to 
distinguish from water-speciﬁ c T2 obtained with 
methods eliminating the fat signal.34 Our data from 
muscles with fat fraction below the 95th percentile of the 
control range suggest that adjustment for T2 and MTR 
dependence on residual fat fraction shows signiﬁ cant 
diﬀ erences between patient and control groups 
independent of fat fraction. These diﬀ erences, greater for 
the inclusion body myositis group but also signiﬁ cant in 
Charcot-Marie-Tooth 1A, might represent early changes 
in muscle water distribution occurring before signiﬁ cant 
intramuscular fat accumulation. These changes might be 
reversible with therapy,35 and muscle T2 and MTR might 
thus provide useful biomarkers in clinical trials focused 
on early or active disease.
This study had several limitations. We analysed data 
from only single slices of thigh and calf blocks, with only 
small ROI for T2 and MTR sequences. This might have 
contributed to variation if muscle pathology was 
anatomically non-homogeneous. To ensure consistency 
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in the volumes of tissue assessed longitudinally, slice 
positions were deﬁ ned by measured distance from bony 
landmarks, a more reliable method than surface 
anatomy-based slice positioning,36 and follow-up ROIs 
were drawn with direct reference to the baseline ROI. T2 
estimation by sampling two turbo-spin echo images is 
potentially less accurate than the Carr-Purcell-Meiboom-
Gill multiple-spin-echo method.37 However, our approach 
provides time-eﬃ  cient, wide-coverage quantiﬁ cation of 
T2 change using a method that can be implemented on 
standard MRI systems without specialist modiﬁ cation. 
Outcome measure SRMs derived from observational 
studies are applicable to interventional studies only when 
the intervention will aﬀ ect the outcome measurement. 
For example, if an intervention had an eﬀ ect on muscle 
that improved strength without an eﬀ ect on muscle size 
or quantitative MRI variables, a functionally important 
beneﬁ t might have been missed. This association will 
need to be established in a disease-speciﬁ c and 
intervention-speciﬁ c manner.
Chronic intramuscular fat accumulation is common 
to a wide range of neuromuscular disorders. Although 
the precise molecular events responsible for 
intramuscular fat accumulation are not fully understood, 
one mechanistic study38 suggests that a range of 
diﬀ erent primary genetic muscle diseases, and 
potentially denervation, stimulate muscle precursor 
stems cells to diﬀ erentiate into adipose cells and 
ﬁ broblasts. That intramuscular fat accumulation seems 
to be a common pathway in many genetic and acquired 
neuromuscular disorders, underlines its potential 
usefulness as an outcome measure across neuro-
muscular disorders. As an example, we have shown 
here that the same types of change can be quantiﬁ ed in 
these two diﬀ erent muscle wasting diseases: an acquired 
late-onset progressive proximal and distal myopathy 
(inclusion body myositis) and an inherited childhood-
onset slowly progressive distal predominant neuropathy 
(Charcot-Marie-Tooth 1A).
Although diﬀ erences between diseases result in 
diﬀ erent distributions and degrees of muscle 
abnormalities, their presence, direction, and clinical 
correlations are consistent (panel 2), making these 
outcome measures potentially applicable across other 
neuromuscular disorders with lower limb weakness. 
Through selection of MRI variables targeted to disease 
and intervention, MRI outcome measures can be 
optimised to provide maximum responsiveness for a 
speciﬁ c clinical trial. For example, in Charcot-Marie-
Tooth 1A, in which the absence of signiﬁ cant MRI 
abnormalities at thigh level is a reﬂ ection of the length-
dependent distribution of weakness, the optimum MRI 
protocol would include assessment of fat inﬁ ltration of 
calf muscles with a sequence such as 3-point Dixon. In 
inclusion body myositis, to assess whether an 
intervention reversed acute pathological processes, 
additional water-sensitive sequences such as T2 or MTR 
quantiﬁ cation should be included. In this study, T2 and 
MTR measurements showed similar responses, so the 
additional beneﬁ t of measuring both sequences remains 
unproven. For any speciﬁ c neuromuscular disorders, 
understanding of basic disease mechanisms, disease 
distribution of the aﬀ ected muscles, and treatment 
mechanisms will enable trial-speciﬁ c selection of MRI 
outcome measures and appropriate anatomical imaging 
levels to provide optimum responsiveness.
In these representative neuromuscular disorders, the 
comprehensive MRC Centre MRI protocol provides 
outcome measures closely correlated to strength, function, 
and disease severity at baseline and longitudinally. In 
Charcot-Marie-Tooth 1A, responsive ness far exceeded that 
of existing outcome measures. This ﬁ nding might allow 
Panel 2: Research in context
Systematic review
We searched PubMed for reports published before July 1, 2015, with the MeSH terms 
“magnetic resonance imaging” and “Charcot-Marie-Tooth disease”, “myositis, inclusion 
body”, or “neuromuscular diseases”, with no language restrictions. We restricted our 
search to reports in human participants. Five articles were identiﬁ ed reporting skeletal 
muscle MRI in inclusion body myositis, but none included quantitative MRI sequences 
and none included longitudinal data. 12 articles were identiﬁ ed reporting skeletal muscle 
MRI in Charcot-Marie-Tooth 1A. Only two of these14,39 used quantitative MRI sequences 
but did not include longitudinal data. Of the ten studies reporting qualitative MRI in 
Charcot-Marie-Tooth 1A, one study included a longitudinal scan on a single patient,40 
whereas one study reported qualitative MRI imaging in 14 patients at a 2 year interval but 
identiﬁ ed no progression.41 Taking into account all neuromuscular disorders, published 
quantitative MRI studies have quantiﬁ ed fat fraction,9–13 T2,9,11,29,30,42,43 and magnetisation 
transfer ratio,14,44 in disorders that are myopathic,9–13,29,30,42–44 neuropathic,10,14 
inherited,9–14,29,30,42,44 or acquired,14,43 at thigh level10,11,13,30,42,43 or calf level,9,11,14,29,42,44 in one 
muscle9,10,29 or many muscles,11–14,30,42–44 and with controls9,11,14,29,42,43,44 or without 
controls.10,12,13,30 Few studies in patients with neuromuscular disorders have been published 
so far with longitudinal quantitative MRI data.13,15,45,46 Observational studies have shown 
longitudinal change in muscle fat fraction in patients with limb girdle muscular dystrophy 
type 2I,13 and longitudinal change in muscle T2 in Duchenne muscular dystrophy.15 Studies 
in Duchenne have used MRI longitudinally after steroid initiation and showed a reduction 
in T245 or a variable eﬀ ect on T2.46
Interpretation
Accurately and reliably monitoring disease progression is an important barrier to 
successful experimental clinical trials to test new therapies for muscle-wasting 
neuromuscular diseases. We report longitudinal data in patients with one of two 
representative neuromuscular disorders and healthy controls. We have systematically 
investigated quantitative MRI biomarkers and have shown they can reliably and 
accurately track disease progression. In patients with Charcot-Marie-Tooth 1A, calf muscle 
fat fraction showed high responsiveness, exceeding all clinical measures. Abnormalities in 
T2 and MTR, measures sensitive to muscle water accumulation, were seen in muscles 
before signiﬁ cant fat inﬁ ltration. We have also shown correlations with important 
measures of patient function including strength, functional scores, and quality of life 
measures. The biomarkers we selected detect and quantify water and fat accumulation 
within muscle, which both occur across a range of diﬀ erent muscle-wasting diseases. 
Therefore these quantitative MRI methods might be applicable to other muscle-wasting 
neuromuscular diseases. 
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progress in the design of adequately powered clinical 
trials in this gradually progressive but debilitating disease. 
In inclusion body myositis, T2 and MTR showed early 
changes in muscles before signiﬁ cant intramuscular fat 
accumulation, providing potential measures of early 
disease before irreversible changes have occurred. 
Together, the methods provide objective, non-invasive, 
valid, responsive outcome measures in inclusion body 
myositis and Charcot-Marie-Tooth 1A.
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